IOVA

Iovance Biotherapeutics Inc

Add to Watchlist

Advanced Chart

3.130

-0.16(-4.863%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.450

Open

3.415

VWAP

Vol

24.94M

Mkt Cap

1.05B

Low

2.970

Amount

EV/EBITDA(TTM)

Total Shares

279.83M

686.50M

EV/OCF(TTM)

P/S(TTM)

4.47

Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

92.17M

+25.07%

-0.202

-22.27%

78.32M

+33.76%

-0.251

-10.4%

67.14M

+115.84%

-0.276

-18.69%

Estimates Revision

The market is revising Downward the revenue expectations for Iovance Biotherapeutics, Inc. (IOVA) for FY2025, with the revenue forecasts being adjusted by -36.89% over the past three months. During the same period, the stock price has changed by -13.30%.

Revenue Estimates for FY2025

Revise Downward

-36.89%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+38.23%

In Past 3 Month

Stock Price

Go Down

-13.30%

In Past 3 Month

11 Analyst Rating

197.12% Upside

Wall Street analysts forecast IOVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOVA is 9.30 USD with a low forecast of 1.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

4 Hold

1 Sell

Moderate Buy

197.12% Upside

Current: 3.130

Low

1.00

Averages

9.30

High

25.00

197.12% Upside

Current: 3.130

Low

1.00

Averages

9.30

High

25.00

Goldman Sachs

Neutral -> Sell

downgrade

$8 -> $1

2025-07-15

Reason

Goldman Sachs

Price Target

$8 -> $1

2025-07-15

downgrade

Neutral -> Sell

Reason

Goldman Sachs downgraded Iovance Biotherapeutics to Sell from Neutral with a price target of $1, down from $8. The firm cites the slower than expected launch of the company's lead drug Amtagvi in second-line melanoma for the downgrade. Key opinion leader discussions and a physician survey indicate underutilization of Amtagvi due to a limited eligible patient population as well as logistical and operational complexities, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$20

2025-07-14

Reason

H.C. Wainwright

Price Target

$20

2025-07-14

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating on Iovance Biotherapeutics with a $20 price target after the company announced real-world, retrospective data from patients treated with commercial Amtagvi. The drug demonstrated "impressive" clinical responses, particularly in earlier stage patients, the analyst tells investors in a research note. The firm points out that among 41 evaluable patients treated at four authorized treatment centers, the physician-assessed objective response rate was 48.8%. It believes Amtagvi is working as intended, and even exceeding expectations in less heavily treated patients, post commercialization.

UBS

David Dai

Buy -> Neutral

downgrade

$17 -> $2

2025-05-16

Reason

UBS

David Dai

Price Target

$17 -> $2

2025-05-16

downgrade

Buy -> Neutral

Reason

UBS analyst David Dai downgraded Iovance Biotherapeutics to Neutral from Buy with a price target of $2, down from $17. The company's Q1 Amtagvi sales were below expectations and its fiscal 2025 guidance was reduced, indicating a slower Amtagvi ramp, the analyst tells investors in a research note. The firm believes the slower ramp is driven by implementation issues and activations of smaller authorized treatment centers, which may be hampered by insufficient hospital infrastructure. UBS cites lower Amtagvi sales estimates for the downgrade.

Barclays

Peter Lawson

Overweight

downgrade

$5 -> $4

2025-05-12

Reason

Barclays

Peter Lawson

Price Target

$5 -> $4

2025-05-12

downgrade

Overweight

Reason

Truist

Buy

Hold

downgrade

2025-05-12

Reason

Truist

Price Target

2025-05-12

downgrade

Buy

Hold

Reason

Mizuho

Outperform

NULL

downgrade

$30 -> $10

2025-05-12

Reason

Mizuho

Price Target

$30 -> $10

2025-05-12

downgrade

Outperform

NULL

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Iovance Biotherapeutics Inc (IOVA.O) is -3.37, compared to its 5-year average forward P/E of -8.14. For a more detailed relative valuation and DCF analysis to assess Iovance Biotherapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.14

Current PE

-3.37

Overvalued PE

-2.79

Undervalued PE

-13.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.86

Current EV/EBITDA

-2.21

Overvalued EV/EBITDA

-2.12

Undervalued EV/EBITDA

-11.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

42.71

Current PS

3.22

Overvalued PS

170.88

Undervalued PS

-85.47

Financials

Annual

Quarterly

FY2025Q1

YoY :

+6798.46%

49.32M

Total Revenue

FY2025Q1

YoY :

+2.97%

-121.22M

Operating Profit

FY2025Q1

YoY :

+2.82%

-116.16M

Net Income after Tax

FY2025Q1

YoY :

-14.29%

-0.36

EPS - Diluted

FY2025Q1

YoY :

-13.08%

-109.91M

Free Cash Flow

FY2025Q1

YoY :

-99.91%

-0.85

Gross Profit Margin - %

FY2025Q1

-163.39

FCF Margin - %

FY2025Q1

YoY :

-98.51%

-235.51

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

503.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 296.59% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

9.4M

Volume

6-9

Months

7.2M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

5.3M

Volume

Months

6-9

1.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

503.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

IOVA News & Events

Events Timeline

2025-07-15 (ET)

2025-07-15

07:37:20

Iovance Biotherapeutics appoints Roche as CFO

2025-07-14 (ET)

2025-07-14

07:37:05

Iovance Biotherapeutics announces real-world study data on Amtagvi

2025-06-02 (ET)

2025-06-02

09:40:33

Iovance Biotherapeutics announces publication of five-year analysis of Amtagvi

News

8.0

07-23NASDAQ.COM

Noteworthy Wednesday Option Activity: AFRM, ADI, IOVA

4.5

07-23NASDAQ.COM

Wednesday Sector Leaders: Computer Peripherals, Biotechnology Stocks

9.5

07-23Benzinga

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday